
Sign up to save your podcasts
Or


Vlad Coric, M.D., CEO of Biohaven Pharmaceuticals, joins Venrock partner Nimish Shah to speak about the significance of innovation and creativity across all aspects of a business. Coric dives into the challenges of launching Biohaven's drug, Nurtec ODT, during the pandemic and why he believed it was their moral duty to continue the drug supply chain, despite the lockdown. Still seeing patients today, Coric discusses how his patient-centric approach positively guided him as a drug developer. Coric touches on Biohaven's collaboration with Khloe Kardashian for Nurtec's launch and his excitement for the digital transformation occurring in biotech. Coric also advises other biotech CEOs raising a cross-over round or going public to be selective with the investors they invite in, as they become an extension of the team.
By Venrock, a venture capital firm4.8
6262 ratings
Vlad Coric, M.D., CEO of Biohaven Pharmaceuticals, joins Venrock partner Nimish Shah to speak about the significance of innovation and creativity across all aspects of a business. Coric dives into the challenges of launching Biohaven's drug, Nurtec ODT, during the pandemic and why he believed it was their moral duty to continue the drug supply chain, despite the lockdown. Still seeing patients today, Coric discusses how his patient-centric approach positively guided him as a drug developer. Coric touches on Biohaven's collaboration with Khloe Kardashian for Nurtec's launch and his excitement for the digital transformation occurring in biotech. Coric also advises other biotech CEOs raising a cross-over round or going public to be selective with the investors they invite in, as they become an extension of the team.

1,284 Listeners

2,705 Listeners

2,461 Listeners

1,096 Listeners

339 Listeners

323 Listeners

389 Listeners

5,554 Listeners

10,041 Listeners

34 Listeners

528 Listeners

21 Listeners

292 Listeners

473 Listeners

1,425 Listeners